Loading clinical trials...
Loading clinical trials...
Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Start Date
August 5, 2023
Primary Completion Date
October 25, 2023
Completion Date
October 30, 2023
Last Updated
September 21, 2023
4,201
ESTIMATED participants
Azvudine
DRUG
Lead Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287